Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients

Liver International

Volumn 35, Issue 2, 2015, Pages 591-600

  Weinmann, Arndt ^a   Koch, Sandra ^a   Sprinzl, Martin ^a   Kloeckner, Roman ^a   Schulze Bergkamen, Henning ^b   Düber, Christoph ^a   Lang, Hauke ^a   Otto, Gerd ^a   Wörns, Marcus A ^a   Galle, Peter R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

HCC; SIRT; TACE; BCLC; Epidemiology; Hepatocellular carcinoma; Liver transplantation; Sorafenib; Survival; Therapy

Indexed keywords

ALBUMIN; ALCOHOL; BILIRUBIN;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CHILD PUGH SCORE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; ICD-10; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; EUROPE; EVALUATION STUDY; LIVER NEOPLASMS; NONPARAMETRIC TEST; PROCEDURES; PROGNOSIS; REGRESSION ANALYSIS;

CARCINOMA, HEPATOCELLULAR; EUROPE; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 84921506801     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12696     Document Type: Article

References (24)

1. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-96.
2. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-32.
3. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011; 34: 422-31.
4. Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010; 42(Suppl. 3): S258-63.
5. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
6. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-15.
7. Chevret S. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31: 133-41.
8. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
9. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
10. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
12. Greten T F, Malek N. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des hepatozellulären Karzinoms, Langversion 1.0, AWMF Registrierungsnummer: 032-053OL. 2013.
13. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
14. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
15. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma trated by transarterial chemoembolization (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5.
16. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
17. Raoul J-L, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2010; 37: 212-20.
18. Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-59.
19. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
20. Bruix J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-30.
21. Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol 2013; 59: 279-84.
22. Piscaglia F, Terzi E, Cucchetti A, et al. Treatment of hepatocellular carcinoma in Child-Pugh B patients. Dig Liver Dis 2013; 45: 852-8.
23. Gugenheim J, Bredt LC, Iannelli A, et al. Recurrence after liver transplantation for hepatocellular carcinoma according to up-to-seven criteria. Hepatogastroenterology 2013; 60: 799-806.
24. Dufour J-F, Bargellini I, De Maria N, et al. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 2013; 24:ii24-9.